PVT201 / Parvus Therap - LARVOL DELTA

A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, andnPharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in primary biliary cholangitis/primary sclerosing cholangitis patients. (ANZCTR) - P1 | N=6 | Withdrawn | Sponsor: Parvus Therapeutics, Inc. | Not yet recruiting ➔ Withdrawn

First-in-human • Trial withdrawal • Hepatology • Immunology • Primary Biliary Cholangitis

Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Parvus Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • Hepatology • Immunology • Primary Biliary Cholangitis

A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects. (ANZCTR) - P1 | N=24 | Completed | Sponsor: Parvus Therapeutics, Inc. | Not yet recruiting ➔ Completed | N=36 ➔ 24

Enrollment change • Trial completion • Trial initiation date • Hepatology • Immunology • Primary Biliary Cholangitis

Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Parvus Therapeutics, Inc. | Trial completion date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Hepatology • Immunology • Primary Biliary Cholangitis

Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Parvus Therapeutics, Inc.

New P1 trial • Hepatology • Immunology • Primary Biliary Cholangitis

A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects (ANZCTR) - P1 | N=36 | Not yet recruiting | Sponsor: Parvus Therapeutics, Inc.

New P1 trial • Hepatology • Immunology • Primary Biliary Cholangitis